The GRACE (GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS) study recently opened in the CPCCRN network. The purpose of this study is to establish the immunologic efficacy of GM-CSF administered by the IV and SQ routes in children with immunoparalysis in the setting of sepsis-induced MODS. This is because despite advances in pediatric sepsis care, children who develop sepsis-induced multiple organ dysfunction syndrome (MODS) face mortality rates as high as 20-50%.This study plans to enroll 180 subjects over approximately 3 years across all 8 network sites. Enrollment began in March and there have been 15 subjects enrolled so far.
